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DOI 10.1016/j.ccr.2010.10.035SUMMARYIt has been proposed that an aggressive secondary cancer stem cell population arises from a primary cancer
stem cell population through acquisition of additional genetic mutations and drives cancer progression.
Overexpression of Polycomb protein EZH2, essential in stem cell self-renewal, has been linked to breast
cancer progression. However, critical mechanism linking increased EZH2 expression to BTIC (breast tumor
initiating cell) regulation and cancer progression remains unclear. Here, we identify a mechanism in which
EZH2 expression-mediated downregulation of DNA damage repair leads to accumulation of recurrent
RAF1 gene amplification in BTICs, which activates p-ERK-b-catenin signaling to promote BTIC expansion.
We further reveal that AZD6244, a clinical trial drug that inhibits RAF1-ERK signaling, could prevent breast
cancer progression by eliminating BTICs.INTRODUCTION
Accumulated evidence shows that cancer stem/progenitor
cells (or tumor initiating cells, TICs) account for cancer initiation,
progression, and drug resistance (Al-Hajj andClarke, 2004; Reya
et al., 2001; Rossi et al., 2008). TICs in different types of cancers
have been gradually identified, for example, breast tumor initi-
ating cells (BTICs) can be isolated by sorting for CD44+CD24-/low
cells (Al-Hajj et al., 2003) or Hoechst negative side population
(SP) cells (Patrawala et al., 2005), and can also be enriched by
suspension in spheroid culture termed mammospheres and
serial transplantations in immunodeficient mice (Ponti et al.,Significance
Tumor initiating cells are suggested to be responsible for init
enhanced expression of Polycomb protein EZH2 in BTICs (br
damage repair protein and accumulation of genomic abnorma
enin) promoting BTIC expansion and cancer progression. Our
vironment, such as hypoxia, may promote BTICs through upreg
linking a specific genomic aberration mediated by EZH2-impair
this study reveals a previously unidentified therapeutic effect
progression by eliminating BTICs and elucidates important cli
86 Cancer Cell 19, 86–100, January 18, 2011 ª2011 Elsevier Inc.2005). Compared with differentiated cells/nonstem cells with
limited opportunity to accumulate multiple lesions, long-lived
stem/progenitor cells allow progression toward malignancy
through accumulation of epigenetic or genetic alterations that
deregulate self-renewal pathways (Rossi et al., 2008). It was
proposed that a more aggressive secondary cancer stem/
progenitor cell population may arise from a primary cancer
stem cell population through acquisition of additional genetic
mutations that deregulate cancer stem/progenitor homeostasis
and drive cancer progression (Visvader and Lindeman, 2008).
Moreover, studies showed that high-grade tumors are enriched
with a high content of TICs (Pece et al., 2010). However, the keyiation and aggressive progression of cancer. We show that
east tumor initiating cells) results in downregulation of DNA
lities that mediate deregulated signaling (RAF1-ERK-b-cat-
findings also indicate that the cancer-predisposed microen-
ulating EZH2 expression. Our data further provide evidences
ed DNA damage response to expansion of BTICs. Together,
of RAF1-ERK signaling inhibitors to prevent breast cancer
nical implications.
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formation or expansion are largely unknown.
Epigenetic regulation by Polycomb proteins is essential in
maintaining the self-renewal capability of embryonic and adult
stem cells through mediating histone methylation at lysine 27
of histone H3 (H3K27) (Cao and Zhang, 2004; Ezhkova et al.,
2009; Lessard and Sauvageau, 2003; Sparmann and van Lohui-
zen, 2006). Interestingly, high expression of EZH2, a key compo-
nent of the Polycomb PRC2 complex, has been linked to aggres-
sive progression of breast and prostate cancers (Kleer et al.,
2003; Varambally et al., 2002). However, critical mechanisms
linking increased EZH2 expression to BTIC regulation and
cancer progression remain unclear.
The importance of the tumor microenvironment in cancer has
been increasingly recognized (Hu and Polyak, 2008). The micro-
environment of solid tumors contains regions of poor oxygena-
tion as a result of hypoxia. Note that hypoxia/HIF1a activation
is associated with high-grade basal breast cancer and poor
prognosis (Bristow and Hill, 2008). Using microarray-based
gene expression profiles, previous studies have identified a
group of DNA damage repair genes that are downregulated by
hypoxia, including RAD51 (Bindra et al., 2004, 2007; Bindra
and Glazer, 2007). Interestingly, forced expression of EZH2 in
breast epithelial cells correlates with decreased expression of
double-strand-break repair protein RAD51 paralogs through an
unknown mechanism (Zeidler et al., 2005). Whether hypoxia
associates with EZH2 on regulation of DNA damage repair
remains to be explored. More importantly, disruption of critical
DNA damage repair proteins, such as RAD51, is expected to
result in a significant increase of spontaneous chromosomal
break and chromosome instability (Dodson et al., 2004), which
could further lead to oncogenic translocation and amplification
(Difilippantonio et al., 2002).
This study is to identify a mechanism linking increased EZH2
expression to BTIC regulation and cancer progression.
RESULTS
Increased EZH2 Expression in BTICs Is Linked to
Decreased RAD51 Expression, Enhanced BTICs, and
High-Grade Breast Cancer
To understand whether EZH2 expression is involved in regula-
tion of BTICs and cancer progression, we examined the endog-
enous EZH2 expression level in the CD44+CD24-/low cells iso-
lated from human breast cancer and noncancer cell lines,
xenograft tumor cells, and primary breast tumor cells. We found
that EZH2 levels in the CD44+CD24-/low cells positively correlate
with the percentage of CD44+CD24-/low cells (Figure 1A). EZH2
expression was also enriched in the primary tumor cell popula-
tions highly expressing ALDH1 (ALDH+) and OCT4 (OCT4+)
(see Figure S1A available online), both of which are known
markers of cancer stem cells/stem cells (Wicha, 2008). These
data suggest EZH2 expression level may play a role in regulating
the BTIC population.
We then investigated whether EZH2 enables the accumulation
of genomic/genetic abnormalities to promote BTICs through re-
pressing RAD51. Thus, similar to Figure 1A, we examined the
endogenous RAD51 expression levels in the CD44+CD24-/low
cells isolated from the abovementioned samples. We foundthat EZH2 expression was negatively correlated with RAD51
expression in the CD44+CD24-/low cells (Figure 1B). Furthermore,
EZH2 expression was most elevated whereas RAD51 expres-
sion was most repressed in the CD44+CD24-/low cells isolated
from high-grade/basal-like breast cancer cells (Figures 1A and
1B), which are known to be associated with aggressive malig-
nancy, high tumor grade, and poor prognosis, compared with
those from less invasive/low tumor grade breast cancer cells
and to those from benign mammary cell line (Figures 1A and
1B). Consistent with the primary cells and cell line data, high
EZH2 expression was also significantly correlated with high
tumor grade in a cohort of humanbreast tumor sections (Table 1),
where EZH2 expression was negatively correlated with RAD51
expression (Table 2). Together, these data suggest a link
between EZH2 and RAD51 expression in the regulation of BTICs
and cancer progression.
Elevated Expression of EZH2 in BTICs Downregulates
RAD51 Expression and Increases Genomic Abnormality
To investigate if elevated EZH2 expression indeed plays a role
in promoting BTICs, human primary tumor cells enriched for
BTICs by sorting with CD44+CD24-/low marker were infected
with retrovirus expressing EZH2 or other indicated constructs
(Figure S1B), and then maintained in suspension culture to
produce mammospheres. Mammospheres still contained 87%
CD44+CD24-/low cells after 7 days of culture in suspension and
could be differentiated in conditions as previously described
(Dontu et al., 2003) and (Ponti et al., 2005) (Figure S1C). To
ensure EZH2 expression level is physiological relevant, we
purposely increased the EZH2 level in the low tumor grade BTICs
(PT1) to a level that is comparable to the physiologically high
EZH2 level in the high tumor grade BTICs (PT2) (PT1+EZH2
versus PT2, Figure 1C). We found that ectopic expression of
EZH2 downregulated RAD51 mRNA and protein in the BTICs
from human primary tumor cells (Figure 1D, left and upper right),
whereas knocking down EZH2 using small hairpin RNA (shRNA)
increased RAD51 mRNA and protein expression (Figure 1D, left
and lower right). Through chromatin immunoprecipitation (ChIP),
we found that the PRC2 complex proteins including EZH2 and
SUZ12 as well as PRC1 component (BMI1) (Figure 1E) were re-
cruited and bound to the putative Polycomb response element
(PRE) containing PHO motif and GAGA motif within the RAD51
promoter (Figure S1D) (Sing et al., 2009), where EZH2 and
H3K27Me3 co-occupied (Figure 1F). In addition, RAD51 tran-
scription was suppressed by wild-type EZH2 but not by the
methyl-transferase deleted mutant (ΔSET), suggesting that
H3K27 histone methylation mediated by EZH2 involves in the
silencing of RAD51 transcription (Figure S1E). Accordingly,
downregulation of EZH2 by shRNA reduced H3K27 histone
methylation within RAD51 promoter (Figure 1E), which could
thereby increase RAD51 expression as shown in Figure 1D.
To determine the biological effects resulting from EZH2-
RAD51 regulation, we examined changes in DNA lesions/aberra-
tions given the critical role of RAD51 in DNA damage repair. We
found that EZH2-mediated downregulation of RAD51 induced
a substantial amount of spontaneous DNA damage indicated
by the increased comet tail formation, which was blocked by co-
expression of a retroviral promoter driven-RAD51 plasmid that is
free from the transcriptional repression by EZH2 (Figure 1G).Cancer Cell 19, 86–100, January 18, 2011 ª2011 Elsevier Inc. 87
H5413133EZH2+RAD51
8221647EZH2
2917131VEC
Total abnormalities (%)MetaphasesTranslocationsDeletionsBreaks
*
RAD51 
RAD51 
EZH2 IgG Input
IP
Primary IP: EZH2
Secondary IP
Input    IgG H3K27Me3
G VEC            EZH2       EZH2+RAD51
V
E
C
E
Z
H
2
E
Z
H
2
+
R
A
D
5
1
**
0
1
2
3te
m
o
c
f
o
e
g
n
a
h
c
dl
o
F
sll
e
c
e
vi
ti
s
o
p
A B
S
h
-
E
Z
H
2
S
h
-
E
Z
H
2
E
Z
H
2
V
E
C
E
Z
H
2
V
E
C
α-EZH2 α-H3K27Me3
RAD51
*
*
0
10
20
30
40)
%
(
t
u
p
n
I
/
d
n
u
o
B
*
*
S
h
-
E
Z
H
2
E
Z
H
2
Input
V
E
C
IgG
EZH2
SUZ12
H3K27Me3
RAD51
GAPDHEZH2
P
I
BMI1
0
2
4
6
8
10
12
)
%
(
t
u
p
ni
l
a
ni
gi
r
O/
d
n
u
o
B
α
- α
-
α
-
α
-
α
-E
Z
H
2
gI
G
gI
G
E
Z
H
2
&
H
3
K
2
7
M
e
3
D
sh-
EZH2
RAD51
Tubulin
VEC
EZH2
EZH2
RAD51
Tubulin
EZH2VEC
0
0.5
1
1.5
2
2.5
1
5
D
A
R
f
o
e
g
n
a
h
c
dl
o
F
A
N
R
m
S
h
-
E
Z
H
2
E
Z
H
2
V
E
C
V
E
C
RAD51
*
*
F
C
R= 0.93
0
20
40
60
80
100
0 20 40 60 80 100
CD24-CD44+ cell abundance (%)
n
i
n
o
i
s
s
e
r
p
x
e
2
H
Z
E
e
v
i
t
a
l
e
R
s
l
l
e
c
+
4
4
D
C
-
4
2
D
C
PT1
PT2
r=0.93
P=0.03
PT3
R= -0.85
0
20
40
60
80
100
0 20 40 60 80
Relative RAD51 expression in
 CD24-CD44+ cells
n
i
n
o
i
s
s
e
r
p
x
e
2
H
Z
E
e
v
i
t
a
l
e
R
s
l
l
e
c
+
4
4
D
C
-
4
2
D
C
PT1
PT2
r=-0.76
P=0.04
PT3
0
10
20
30
40
50
h
ti
w
sll
e
c
f
o
e
g
a
t
n
e
c
r
e
P
2
>
e
m
o
s
o
r
t
n
e
c
d
ei
fil
p
m
a
**
Endogenous EZH2: +-
I
EZH2
-
EZH2
+
E
APC A
00 101 102 103 104
PT1
PT2
PT1+VEC
PT1+EZH2
EZH2 expression
Figure 1. Elevated Expression of EZH2 in BTICs Reduces RAD51 Expression and Increases Genomic Abnormality
(A and B) Intracellular staining correlating EZH2 expression with the percentage of CD44+CD24-/low cell population (A) or with RAD51 expression in CD44+CD24-/low
cells from high-grade tumor cells (B) using flow cytometry. Solid circle: Patient Tumor-PT2, basal-like breast cancer cells MDA-MB-231, Hs578t, BT549, BT549
xenograft tumor cells; dotted circle: Patient Tumor-PT1, Patient Tumor-PT3, low-grade breast cancer cell lines SKBR3, MCF7, MCF7 xenograft tumor cells, and
benign mammary cells MCF10A.
(C–G) (C) Intracellular staining shows endogenous EZH2 and ectopically expressing EZH2 levels in CD44+CD24-/low population isolated from human primary tumor
cells. Infected human primary tumor cells in suspension culture enriched for CD44+CD24-/low were subjected to (D) real-time PCR and immunoblotting; (E and F)
chromatin immunoprecipitation (ChIP, PCR product encompassing GAGA motif); (G) comet analysis shown as representative fluorescence microscopy images
(scale bar: 5 mm).
(H) Table summarizing the percentage of CD44+CD24-/low enriched-human primary tumor cells exhibiting chromosome aberrations per metaphase by karyotype
analysis (n = 6, duplicate in each group).
(I) Percentage of the cells with amplified red-CEP3 centrosomes with high or low EZH2 expression (eight breast tumor sections/group, 50 nuclei were counted in
each section; n > 2 per nucleus is considered as amplification, scale bar: 5 mm). Endogenous EZH2 expression was determined by immunohistochemical staining
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Table 1. EZH2 Expression Is Positively Correlated with Tumor
Grade
Tumor Grade I II and III Total
EZH2 negative/low 13 (10.2%) 24 (18.7%) 37 (28.9%)
EZH2 high 13 (10.2%) 78 (60.9%) 91 (71.1%)
Total 26 (20.4%) 102 (79.6%) 128 (100%)
Expression patterns of EZH2 and tumor grade in the consecutive
sections from 128 human breast tumors were determined and summa-
rized. (-): negative-low, (+): positive-high. The correlation between
EZH2 and tumor grade was analyzed using SPSS 16.0 Pearson Chi-
Square test. p < 0.008.
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EZH2 Promotes Breast Tumor Initiating CellsFurthermore, ectopic EZH2 expression in BTIC-enriched cells
significantly increased chromosome karyotype aberrations,
including chromosome breaks, deletions and translocations,
which were reduced by coexpression of RAD51 (Figure 1H,
representative morphology of abnormal karyotypes is shown in
Figure S1F). Next, we inquired whether physiological expression
level of EZH2 is also related to chromosomal abnormalities in
a cohort of tumor samples. It is noted that centrosome amplifica-
tion, a hallmark of genomic instability, has been observed in cells
deficient in DNA damage repair proteins, such as RAD51 (Dod-
son et al., 2004). Thus, we examined endogenous EZH2 level
and centrosome number in a cohort of human breast tumors.
We found that high expression level of endogenous EZH2 signif-
icantly correlates with high centrosome amplification (Figure 1I),
indicating the clinical relevance of EZH2-enhanced genomic
instability in cancer. Taken together, EZH2 likely plays a role in
accumulating genomic abnormalities through repression of
RAD51 expression in the BTIC-enriched population, which may
lead to deregulated signaling required for tumor progression.
Increased EZH2 Expression Enhances Self-Renewal
and Expansion of BTICs
Next, we asked whether EZH2-RAD51 regulation directly affects
BTICs. We found that ectopically expressing EZH2 in human
primary breast tumor cells increased the percentage of SP cells
(Figure 2A) and CD44+CD24-/low cells (Figure 2B), which was
suppressed upon RAD51 coexpression (Figures 2A and 2B).
Similar to ectopically expressing EZH2, knocking down RAD51
significantly enhanced the abundance of SP cells (Figure 2A).
To determine if EZH2 expands BTICs through enhancing the
self-renewing capacity, we examined serially propagated mam-
mosphere formation in vitro and mammary xenograft tumor
formation in vivo using primary tumor cells (PT1). IncreasedTable 2. EZH2 Expression Negatively Correlates with RAD51 but Po
Carcinoma
EZH2
RAD51 RAF1
 +  +
 11 (17.5%) 26 (41.3%) 61 (49%) 2 (2%)
+ 14 (22.2%) 12 (19.0%) 25 (20%) 36 (29%)
Total 26 (39.7%) 38 (60.3%) 86 (69%) 38 (31%)
Expression patterns of EZH2 and RAD51; EZH2 and RAF1; EZH2 and p-E
tumors were determined and summarized. (): negative-low, (+): positive-h
was analyzed using SPSS 16.0 Pearson chi-square test. p = 0.003, p < 0.0expression of EZH2 effectively enhanced primary and secondary
mammosphere formation (Figure 2C), which could generate
xenograft tumors with 10-fold fewer cells than the control group
(Table S3). Moreover, the mammospheres expressing EZH2
contained 2- to 3-fold more cells per sphere, leading to enlarged
sphere size (Figure 2D), and suggesting EZH2 may also promote
BTIC proliferation and/or survival. In contrast, RAD51 coexpres-
sion, at least in part, dampened the EZH2 enhanced mammo-
sphere number and size (Figures 2C and 2D). Similar results
were observed in BTIC-enriched sphere cultures generated
from two other primary tumor samples (data not shown). Taken
together, our data suggest that EZH2 expands highly self-renew-
ing BTICs through the downregulation of RAD51.
Hypoxia Physiologically Increases EZH2 Expression,
Decreases RAD51 Transcription, and Enhances BTICs
To further investigate the physiological relevance of EZH2
expression promotion of BTICs, we looked for physiological
relevant conditions that may be involved in the regulation of
EZH2 expression. Using promoter analysis (Genomatix), we
found a consensus sequence of HIF response element (HRE:
NCGTG) within EZH2 promoter region. To test whether hypoxia
might regulate EZH2 expression, we subjected primary breast
tumor cells (PT1) to normoxic (20% O2) and hypoxic (1% O2)
conditions and found that hypoxia significantly induces lucif-
erase activity driven by EZH2 promoter containing a wild-type
HRE, but not driven by EZH2 promoter with a mutated HRE (Fig-
ure 3A). Mutation of the HRE abolished induction of EZH2 lucif-
erase activity by hypoxia, suggesting HIF transcription factor
may mediate EZH2 activation by hypoxia (Figure 3A). Indeed,
using a specific HIF1a antibody for ChIP analysis, we found
HIF1a directly binds to the HRE-containing EZH2 promoter
under hypoxic conditions (Figure 3B). These data suggest that
upregulated HIF1a upon hypoxia treatment likely transactivates
EZH2 gene and increases EZH2 expression. We next asked
whether hypoxia may induce EZH2 expression in BTICs and
found that the high level of EZH2 was further increased by
hypoxia in CD44+CD24-/low BTICs; however, the EZH2 level re-
mained low in non-CD44+CD24-/low cells even under hypoxia
conditions (Figure 3C). In support of the results in Figure 2,
RAD51 mRNA (Figure 3D) and protein (Figure 3E) levels were
significantly repressed by increased EZH2 expression under
hypoxia in BTIC-enriched cells, and knocking down EZH2 by
shRNA reversed hypoxia-mediated RAD51 repression (Figures
3D and 3E). Knocking down EZH2 also abolished the induction
of BTICs (Figure 3F) and mammosphere formation (Figure 3G)sitively with RAF1, p-ERK, and b-Catenin Expression in Breast
p-ERK b-catenin (C+N)
 +  +
35 (28.2%) 28 (22.6%) 40 (38.1%) 27 (25.7%)
19 (15.3%) 42 (33.9%) 8 (7.6%) 30 (28.6%)
54 (43.5%) 70 (56.5%) 48 (45.7%) 57 (54.3%)
RK; EZH2 and b-catenin in the consecutive sections from human breast
igh. The correlation between EZH2, RAF1, RAD51, p-ERK, and b-catenin
01, p = 0.013, p = 0.001.
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Figure 2. EZH2 Enhances Self-Renewal and Expansion of BTICs
(A and B) Infected human primary breast tumor cells in suspension culture were used to determine the percentage of (A) SP (marked by polygon) and (B)
CD44+CD24-/low (marked by square) populations by flow cytometry.
(C) The number of primary and secondary mammospheres expressing the indicated constructs was counted per 1000 cells (scale bar: 200 mm).
(D) Cell number was counted from dissociated human primary mammospheres collected at the indicated time point (scale bar: 100 mm). Error bars denote ±SD
(*p < 0.05, **p < 0.01).
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EZH2 Promotes Breast Tumor Initiating Cellsby hypoxia, suggesting that hypoxia-mediated EZH2 upregula-
tion was required for both the increased hypoxia-enhanced
CD44+CD24-/low cell population and mammosphere formation.
Together, our results suggest EZH2 expression is induced by
a hypoxic microenvironment, leading to repression of RAD51
(Figures 3D and 3E) and enhancement of BTIC population
(Figures 3F and 3G). These data provide additional support for
the physiological link between induction of EZH2 expression,
repression of RAD51, and enhancement of BTIC population,
which are consistent with the results obtained by using the
ectopic expression system.
EZH2-RAD51 Regulation Induces RAF1 Amplification
and Downstream p-ERK-b-Catenin Activation in BTICs
To further characterize the downstream target(s) that mediate
BTIC promotion by EZH2-RAD51 regulation, we cross refer-
enced the results of two protein arrays generated with lysates
from BTIC-enriched cells expressing EZH2 and shRAD51. Com-
pared with the vector control, ectopically expressing EZH2 or
knocking down RAD51 in BTIC-enriched cells most significantly
increased RAF1 protein expression (Figure 4A; Table S1). Since
downregulation of RAD51 induces double-strand breaks and
chromosome abnormalities, such as gene amplification, we
examined if the enhanced RAF1 expression is due to amplifica-
tion of the RAF1 gene. Using an unbiased SNP array analysis to
examine genomic copy number variation in BTIC-enriched cells
expressing vector control compared with BTIC-enriched cells
expressing EZH2, we found that, indeed, RAF1 gene copy
number was amplified by high EZH2 expression (Figure 4B, left
panel; Table S2), which was further validated by quantitative
PCR analysis using genomic DNA of BTIC enriched cells from
two human primary tumor cells, PT1 and PT3 (Figure 4B, right
panel).
Previously, we showed that activated ERK, a prime target
downstream of RAF1, enhances stabilization of functional b-cat-
enin in the nucleus through inhibiting GSK3b-meidated phos-
phorylation of N terminus of b-catenin (Ding et al., 2005). It is
worth noting that unphosphorylated (activated) b-catenin plays
important roles in maintaining TIC survival, proliferation and
self-renewal (Guo et al., 2008; Li et al., 2003; Reya et al., 2003;
Taipale and Beachy, 2001). Increased unphosphorylated (acti-
vated) b-catenin also contributes to radiation-resistance in
BTICs (Chen et al., 2007). To understand whether EZH2-induced
RAF1 amplification activates the ERK-b-catenin signaling path-
way in BTICs, we examined expression of RAF1, p-ERK and un-
phosphorylated b-catenin by immunoblotting and intracellular
staining using an established antibody that only recognizes
unphosphorylated (activated) b-catenin (Guo et al., 2008;
Chen et al., 2007). Indeed, we found that RAF1 amplification is
concurrently correlated with the upregulation of RAF1 down-
stream targets p-ERK and unphosphorylated b-catenin in
CD44+CD24-/low BTICs isolated from human primary tumor cells
(Figures 4C and 4D). RAF1 amplification potentially resulted from
repressed RAD51 expression by EZH2 as coexpression of
RAD51 blocked activation of p-ERK-b-catenin signaling (Fig-
ure 4C and 4D). Together, these results imply that induced
RAF1 amplification and downstream p-ERK-b-catenin activation
by EZH2-RAD51 regulation in BTICs could contribute to
promoting survival, proliferation, and self-renewal of the BTICs.Increased EZH2 Expression Physiologically Enhances
RAF1-ERK-b-Catenin Signaling in BTICs
To further reveal the physiological relevance between EZH2 and
RAF1-ERK-b-catenin activation in primary BTICs, we examined
the protein levels RAF1, p-ERK and unphosphorylated b-catenin
under EZH2 induction by hypoxia in CD44+CD24-/low cells using
intracellular staining analysis. Consistent with the results shown
in Figure 4D, increased EZH2 expression by hypoxia enhanced
expression of RAF1, p-ERK and unphosphorylated b-catenin,
whereas knocking down EZH2 by shRNA significantly reversed
the hypoxia-activated RAF1-ERK-b-catenin signaling in CD44+
CD24-/low cells (Figure S2A). We found that EZH2 expression
positively correlates with endogenous RAF1 and unphosphory-
lated b-catenin expression in all three BTIC populations from
three individual breast tumor samples (Figure S2B). Together,
these data support the results obtained in the ectopic expression
system (Figure 4D) that increased EZH2 expression in BTICs
resulted in activation of RAF1-ERK-b-catenin signaling.
EZH2-Induced Activation of RAF1-p-ERK-b-Catenin
Signaling Is Positively Correlated with Breast
Cancer Progression
To elucidate the clinical relevance of EZH2 and RAF1-ERK-b-
catenin activation in breast cancer, we first examined associa-
tion between endogenous EZH2 and RAF1 levels by reanalyzing
cDNA Microarray databases from an established human breast
cancer study (Chin et al., 2006). We found that endogenous
EZH2 was highly expressed in aggressive high-stage (stage
3–4) tumors, whereas RAF1 expression was significantly corre-
lated with EZH2 expression (Figure 4E). We next asked whether
overexpression of RAF1 in those tumors expressing high level
of endogenous EZH2 is due to RAF1 amplification at the
genomic level. In a cohort of human breast tumor sections,
over 60% of high-grade (II, III) breast tumors showed high
EZH2 expression (Table 1). These tumors with high level of
endogenous EZH2 frequently exhibited RAF1 gene amplifica-
tion (Figure 4F, right). On the contrary, RAF1 amplification did
not occur in any of the low-grade tumors in which 90% of
them showed none or low EZH2 expression (Table 1). Fur-
thermore, EZH2 expression was negatively correlated with
RAD51 but positively correlated with RAF1, p-ERK, and b-cat-
enin expression in these high-grade, poorly differentiated breast
carcinoma by immunohistochemistry analysis (Figures 4F and
4G and Table 2). Together, these data support the notion that
EZH2, through downregulating RAD51, induces RAF1 amplifi-
cation and downstream p-ERK-b-catenin activation, which
may contribute significantly to promote BTICs and aggravate
breast cancer malignancy.
EZH2-Amplified RAF1 Signaling Enhances Survival and
Proliferation of BTICs
To dissect the dynamics of EZH2-amplified RAF1 signaling in
regulating survival of the BTIC population, we monitored RAF1
gene copy number following the time course of mammospheric
cell division from single cell suspension enriched for BTICs
(Figure S3A). During the first 48 hr after seeding, RAD51 was
repressed by EZH2 expression (Figure S3B), and we ob-
served approximately 1.3- to 1.5-fold more cell death of EZH2-
infected mammospheric cells compared with vector-infectedCancer Cell 19, 86–100, January 18, 2011 ª2011 Elsevier Inc. 91
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Figure 3. Hypoxia Physiologically Increases EZH2 Expression, Decreases RAD51 Transcription, and Enhances Abundance of CD44+
CD24-/low BTICs
Primary tumor cells were treated with normoxia (20% O2) or hypoxia (1% O2) for 48 hr and cultured in suspension for 3 days.
(A) Bar graph showing fold change of EZH2 luciferase reporter analysis. The sequence alignment of HIF response elements within EZH2 promoter is shown
below.
(B) Bar graph showing HIF1a binds to EZH2 promoter using chromatin immunoprecipitation.
(C) Histogram plots showing EZH2 expression in CD44+CD24-/low enriched-human primary tumor cells using surface and intracellular staining. Bars showing
percentage of the indicated protein expression after being normalized to isotype control.
(D) Fold change of mRNA expression using real time PCR in CD44+CD24-/low-enriched human primary tumor cells. VEGF was served as a positive control target
gene for HIF1a.
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which is consistent with a previous report showing that repres-
sion of RAD51 leads to enhanced cell death (Zeidler et al.,
2005). However, we found that the EZH2-infected cells start to
show decreased cell death compared with the vector control
at 72 hr after seeding (Figure S3C) when RAF1 amplification
also evidently occurs (Figure S3D). Additionally, EZH2-infected
CD44+CD24-/low cells showed resistance to etoposide-induced
cell death (Figure S3E), whereas ectopic expression of EZH2 in
non-CD44+CD24-/low led to increased cell death upon etoposide
treatment (Figure S3E), indicating distinct differences between
stem/progenitor cell enriched-populations and nonstem/pro-
genitor cells. Together, these data suggest that enhanced EZH2
expression may amplify RAF1 signaling in BTICs and play a role
in promoting survival of the BTICs.
To further assess the biological function of EZH2-amplified
RAF1 signaling in regulating BTICs, we isolated three distinct
cell populations expressing low EZH2-low RAF1, high EZH2-
low RAF1, and high EZH2-high RAF1 (low EZH2-high RAF1 pop-
ulation is absent) from hypoxia treated-primary tumor cells using
intracellular staining (Figure 5A). We next determined the propor-
tion of the CD44+CD24-/low cells in each of the three populations
and proliferation status of these CD44+CD24-/low cells by BrdU-
FITC staining. Among the three populations (Figure 5A), cells
expressing high EZH2-high RAF1 had the most abundant
CD44+CD24-/low cell population with the highest proliferation
rate (BrdU+) (Figures 5B and 5C). Consistent with this data,
expression of constitutively activated RAF1 (w22) in human
primary tumor cells substantially increasedmammosphere num-
ber and size (Figure 5D). Together, these data support the notion
that amplified RAF1 signaling may not only play a role in
promoting BTIC survival but is also essential for enhancing prolif-
eration of BTICs.A Potential Model of DSB-Induced RAF1 Amplification
and Expansion of RAF1-Amplified BTICs
It was shown that repression of RAD51 leads to decreased DNA
damage repair and increased double-strand breaks (DSB) (van
Gent et al., 2001). DSB generates gene amplification through
a well-established model- Break-Fusion-Bridge (BFB) cycles
(Ford and Fried, 1986). The broken end of the bridge can fuse
to sister chromatid during DNA synthesis and starts a fusion-
bridge cycle (Figure S3F). Each cycle will generate at least an
additional copy of the amplified gene. Given the critical role of
RAD51 in DSB repair, we asked whether RAD51 repression
could lead to RAF1 amplification through DSB-induced BFB
cycles. By using FISH probes targeting RAF1 gene (red) and
a coamplified marker centromeric to RAF1 (green), we found
that EZH2-expressed BTICs show inverted duplication of ampli-
fied RAF1 gene region, a distinct product from BFB process,
suggesting that RAD51 repression leads to RAF1 amplification
through DSB-induced BFB cycles (Figure S3G).
To further understand whether rapid amplification of the RAF
gene occurs in a small number of cells as a result of having(E) Expression change of the proteins in CD44+CD24-/low enriched-population w
(F) The percentage of CD44+CD24-/low population in hypoxia treated-human prim
(G) The number of mammospheres counted per 1000 cells (scale bar: 100 mm). Ea selective advantage to outgrow the population, or whether
there is amplification broadly in the population that somehow
specifically targets the RAF gene by an unknown mechanism,
we monitored dynamic accumulation of RAF1 amplification in
BTICs by FISH (Figure S3H). The number of RAF1-amplified
cells from BTIC-enriched primary tumor cells was graphed
against the generation number for four generations. We found
that RAF1 amplification first occurs in a small population of
BTICs (3%–5% in the first generation) and then expands to
60% in the fourth generation, which suggests an outgrowth
advantage of the RAF1-amplified cell population from EZH2-
expressed BTICs (Figure S3I). Since it was shown that HR
predominantly repairs DSBs in the S phase and that DSBs
caused by HR deficiency are usually replication associated
(Branzei and Foiani, 2008), we think the original BTIC popula-
tion that undergoes replication is likely to be the very first pop-
ulation prone to DSBs and RAF1 amplification. To test this
hypothesis, we costained Vector- or EZH2-infected BTICs in
the first generation with antibodies against BrdU and g-H2AX,
a marker for DSBs. As compared with the Vector-expressed
BTICs that showed no DSB formation (Figure S3J, upper panel),
spontaneous DSBs caused by EZH2 expression predominantly
accumulated in the BrdU-positive cells (Figure S3J, lower
panel). Furthermore, there was around 5%–10% replicating
BTICs in the zero-first generation (Figure S3K), half of which
would have DSBs and potentially generate RAF1 amplification
through BFB cycles in the first generation. This result is consis-
tent with the percentage of RAF1 amplified population (3%–5%)
shown in Figure S3I. These 3%–5% BTICs carrying EZH2-RAF1
amplification had enhanced proliferation and self-renewal,
which enable them to gradually outgrow the other populations
(Figures 2 and 5; Figure S3I). Together, our results suggest
that RAF1 amplification could be a direct result of EZH2-medi-
ated RAD51 repression through accumulation of DSBs followed
by BFB cycles, which may preferentially occur in a replicating
BTIC population.AZD6244 Eliminates BTICs and Mammary Tumor
Formation by Inhibiting RAF1-MEK-ERK-b-Catenin
Activation
To explore if therapeutic agents that block the RAF-b-catenin
activation are able to eliminate EZH2-induced BTIC expansion,
we tested sorafenib (Nexavar), a clinically used RAF inhibitor
and an FDA-approved anti-cancer drug compared with several
clinical cancer therapeutics (imatinib, laptinib, Taxol) and a phar-
macological agent that kills cancer cells by activating p53
(Reactivation of p53 and Induction of Tumor Apoptosis, RITA).
Sorafenib was the most effective in eliminating CD44+CD24-/low
population from BT549 cancer cells (Figure S4A). Sorafenib also
significantly decreased CD44+CD24-/low cells from various basal
breast cancer cell lines (Figure S4B). Additionally, sorafenib pref-
erentially inhibited EZH2 promoted-BTICs which were under
treatment in vitro (Figures S4C–S4D) or were isolated from xen-
ograt tumors of the treated mice in vivo (Figures S4E and S4F).as examined using immunoblotting.
ary tumor cell was determined using flow cytometry.
rror bars denote ±SD (*p < 0.05).
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Figure 4. EZH2-RAD51 Regulation Induces RAF1 Amplification and Downstream p-ERK-b-Catenin Activation, Correlating with Aggravated
Clinical Malignancy
(A) Schematic diagram showing protein array analysis using Panorama (Sigma) antibody arrayswith lysates of the CD44+CD24-/low BTIC enriched-human primary
tumor cells expressing control vector (labeled with Cy3) and EZH2/shRAD51 (labeled with Cy5, n = 4/group).
(B) Diagram showing copy number variation analysis (EZH2/VEC) using SNP array analysis. Results from BTIC enriched-human primary tumor samples (PT1 and
PT3) are presented (left, n = 3/tumor). All vector control samples were examined against twoHapMap normal data sets (Affymetrix) and noRAF1 amplificationwas
observed in any of vector controls. Quantitative genomic DNA copy number analysis was performed in these BTIC enriched-human primary tumor cells using
specific probe against RAF1 gene (right). Samples were collected at 96 hr after EZH2 expression.
Protein expression change in sorted CD44+CD24-/low cells from PT1 was examined using immunoblotting (C) and intracellular staining (D) using flow cytometry.
Bars showing percentage of the indicated protein expression after being normalized to isotype control.
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mation from primary tumor cells as well as from xenograft tumor
cells (Figures S4D–S4F). Furthermore, knocking downRAF1with
shRNAs recapitulated the effect of sorafenib in decreasing
CD44+CD24-/low BTIC population from human primary tumor
cells and also suppressed BTIC xenograft tumor formation
(Figure 6A; Table S3). These data suggest that the RAF1
activation pathway is ubiquitously shared and functionally
important in EZH2-promoted BTICs. To block ERK activation,
we used a specific MEK/ERK inhibitor AZD6244 that has been
tested inmultiple clinical trials.We found that AZD6244 preferen-
tially eliminates EZH2-expressed CD44+CD24-/low cells and
mammospheres (Figure 6B). Furthermore, AZD6244 significantly
decreased p-ERK (Figure 6C) and unphosphorylated b-catenin
(Figure 6C), and also abolished xenograft tumor formation gener-
ated from the primary BTICs that had been pretreated with
AZD6244 (Table S3). To determine if AZD6244 also affects BTICs
in vivo, we applied AZD6244 to the mice bearing xenograft
tumors that were generated from the primary BTICs highly ex-
pressing EZH2. Consistent with the in vitro results, AZD6244 in-
hibited p-ERK (Figure 6D), suppressed CD44+CD24-/low cells
(Figure 6E, left) and abolished formation of mammospheres
(Figure 6E, right and lower panel) which were recovered from
the xenograft tumors in a dose-dependent manner compared
with the vehicle-treated group. All these data suggest that acti-
vation of RAF1-ERK-b-catenin signaling likely plays a role in
promoting BTIC expansion and that inhibiting RAF1-MEK-
ERK-b-catenin activation by AZD6244 or sorafenib eliminates
EZH2-promoted BTICs.
DISCUSSION
Our study reveals a mechanism in which EZH2 promotes BTIC
expansion and cancer progression.We found that RAD51 down-
regulation by EZH2 leads to impaired DNA damage repair and
accumulation of oncogenic hits in favor of promoting BTICs,
such as RAF1-b-catenin activation in BTICs (Figure 6F). These
findings suggest that targeting the EZH2/Polycomb complex
and its downstream activation pathways, such as RAF1-ERK
signaling by AZD6244, may be effective for eliminating BTICs
and intervening breast cancer recurrence.
The long-lived stem/progenitor cells can be a reservoir for
accumulation of the genetic or epigenetic events required for
oncogenic transformation (Rossi et al., 2008). Unrepaired DNA
damage likely allows sufficient oncogenic hits to accrue in
stem/progenitor cells and their progeny. Although it was re-
ported that DNA damage leads to stem/progenitor cell senes-
cence by activating tumor suppressors such as p16INK4a (Rossi
et al., 2008), DNA damage induced by EZH2 overexpression
likely bypasses this defense mechanism through polycomb-(E) Correlation of EZH2 and RAF1 mRNA expression from a cohort of low grade
et al., 2006). Pearson correlation coefficient shows significant correlation r >0.7
(F) A representative case exhibiting breast tumor sections analyzed by immunohis
RAF1 amplification (green) and centromere control (CEP3, red) (corresponding to
from each section. Bar graph showing percentage of the counted nuclei with RA
(G) One hundred twenty-four surgical specimens from breast cancer patients we
sections from a representative case were stained using the indicated antibodies.
and (C): cytoplasmic staining. Error bars denote ±SD (*p < 0.05, **p < 0.01). Seemediated silencing of p16INK4a and p19Arf expression (Bracken
et al., 2007; Tzatsos and Bardeesy, 2008) and thereby prevents
EZH2 expanded-BTICs from exhaustion. Moreover, cancer
stem/progenitor cells show enhanced regulation of ROS scav-
enging (Diehn et al., 2009) and antiapoptosis (Konopleva et al.,
2002) compared with nonstem cell populations. Therefore,
RAF1 amplification induced by RAD51 downregulation may be
a ‘‘necessary but not sufficient’’ effect of RAD51 on BTICs, and
these compensatory mechanisms might help sustain stem/
progenitor cell survival under DNA damage and genomic insta-
bility induced by EZH2 overexpression, which could further
lead to deregulated signaling changes enabling BTICs to
outgrow and expand.
HIF mRNA was shown to be upregulated in the stem cell pop-
ulation from glioma tumors compared with the nonstem cell pop-
ulation (Li et al., 2009), which may provide an explanation for our
observation that EZH2 is highly expressed and induced by
hypoxia in the BTIC population compared with non-BTICs.
Moreover, it was indicated that RAD51 repression by hypoxia
is mediated by repressive E2F4/p130 complexes that bind to
the proximal promoter of the gene. Consistent with this, in our
study, we show that EZH2 binds to RAD51 proximal promoter
which contains a putative Polycomb Response Element (Fig-
ure 1F; Figure S1D). Moreover, we found that E2F4 binds to
EZH2 by immunoprecipitation analysis (data not shown), which
suggest that both EZH2 and E2F4 may mediate RAD51 repres-
sion as a big repressive complex.
Though DNA repair response or expression of certain DNA
damage response/ repair proteins have been reported to be
elevated in cancer stem cells from a couple different models
(Bao et al., 2006; Zhang et al., 2008), few of these molecules
have been functionally characterized. In addition, different
from RAD51-mediated ‘‘error-free’’ DNA repair mechanism, the
increased DNA damage repair capacity in the above-mentioned
studies might be mediated through enhanced ‘‘error-prone’’
DNA damage repair mechanisms, which could in turn to result
in chromosomal aberrations and genomic instability (Aguilera
and Gomez-Gonzalez, 2008; Rassool et al., 2007). Furthermore,
in support of our study, loss of a DSB repair protein BRCA1 has
recentlybeenshowntoexpandmammary luminalprogenitor cells
(Liu et al., 2008). RAD51 is the crucial partner of BRCA1 for medi-
ating the error-free DNA damage repair by homologous recombi-
nation (vanGent et al., 2001). Further studies needed tobecarried
out in order to elucidate the relationship between various DNA
repair mechanisms/molecules and the regulation of BTICs.
The functional association between these amplicons in BTICs
is currently under investigation. Although genomic alterations
have been observed in awide range of humandiseases, genomic
alterations that occur in stem/progenitor cells or tumor initiating
cells are poorly characterized. Among the genomic loci that are(stage 1) and high-grade (stage 3–4) human breast tumors as described (Chin
between expression of RAF1 and EZH2 in high-grade tumors.
tochemical staining (black scale bar: 20 mm) and FISH (white scale bar: 5 mm) for
EZH2 status in Table 1, n = 128). Signal ratio green/red was counted in 50 nuclei
F1 amplification (signal ratio green/red >2).
re analyzed by immunohistochemical staining (scale bar: 50 mm). Consecutive
The staining pattern (): negative-low, (+): positive-high, (N): nuclear staining,
also Figure S2, Table S1, and Table S2.
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Figure 5. EZH2-RAF1 Signaling Promotes Proliferation of BTICs
(A) Human primary tumor cells were hypoxia treated for 48 hr, cultured in suspension for 3 days, and then costained with EZH2 and RAF1 antibodies and
secondary antibodies conjugated with APC and PerCp-Cy5.5, respectively, to determine the indicated protein expression profiles (i, ii, iii) using flow cytometry
(expression pattern: hi: high, lo: low).
(B andC) (B) The percentage of CD44+CD24-/low cells and (C) the percentage of BrdU-FITC-positive CD44+CD24-/low cells for each expression pattern were deter-
mined using flow cytometry. (D) Human primary tumor cells expressing constitutively active pBabe-cRAF-w22 (RAF1w22) were cultured asmammospheres, and
the number of spheres was counted per 1000 cells (scale bar: 100 mm). Error bars denote ± SD (*p < 0.05, **p < 0.01). See also Figure S3.
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12p13.31 gain has been shown to correlate with basal breast
cancer (Chin et al., 2006), and 17q23.1 gain is especially frequent
in BRCA1 associated breast cancer (Sinclair et al., 2002). Partic-
ularly, the RAF1 gene on 3p25.2 was found recurrently amplified
or rearranged in multiple human cancers, where genomic aber-
rant RAF1 gene often associates with cancer aggressiveness
and relapse (Hajj et al., 1990). Activation of RAF-MAPK pathway
is also critical to inducing EMT and metastasis, traits that are
recently associated with stem cell properties (Thiery et al.,
2009). Furthermore, overexpression of wild-type RAF1 is suffi-
cient to induce tumorigenesis in vivo (Kerkhoff et al., 2000), sug-
gesting expression level of RAF1 is a critical parameter for tumor
initiation and development. Based on our and others’ observa-
tions, more than 50% of aggressive breast tumors show EZH2
overexpression (Kleer et al., 2003) (Table 1), and more than
one-third of these tumors exhibit RAF1 amplification (Figure 4F),
which potentially mark the tumorswith high content of BTICs and
aggressivemalignancy. Consistent with the studies showing that
high-grade tumors are enriched in high content of TICs (Pece
et al., 2010), our results suggest that EZH2-amplified RAF1
signaling may play a role in expanding an aggressive subpopula-
tion of BTICs which promotes cancer progression. Therefore,
our study reveals an important clinical implication of using
RAF1/MEK/ERK inhibitor in single agent or in combination for
intervening cancer progression and recurrence.
EXPERIMENTAL PROCEDURES
Cell Culture
Isolation and culture of mammospheres from multiple primary human breast
cancer samples or xenograft tumors were performed as described in Ponti
et al. (2005) and Dontu et al. (2003). Differentiated cell cultures were kept in
DMEM/F12 supplemented with 10% fetal bovine serum on a collagen-coated
dish (BD Biosciences). Primary tumor samples were acquired from breast
cancer patients with informed consent and experimental procedures were
conducted with approval by the University of Texas M. D. Anderson Institu-
tional Review Board.
ChIP Analysis
Chromatin immunoprecipitations were modified from the EZ-CHIP (Upstate)
protocol using antibodies anti-HIF1a (Abcam), anti-EZH2 (Zymed), anti-
SUZ12 (Abcam), anti-Bmi1 (Abcam), and anti-H3K27Me3 (Upstate). For
sequential ChIP, the first elute immunoprecipitated by anti-EZH2 was further
immunoprecipitated by anti-H3K27Me3 and IgG antibodies. The percentage
of the bound DNA was quantified against the original DNA input. Primer
sequences used for ChIP-PCR are as follows: RAD51-50cccccggcataaa
gtttgaat30 (forward); 50gaagcgccgcactctcctta30 (reverse) (PCR product con-
taining polycomb response element) (see Figure S1D). GAPDH promoter
was used as a negative control. For details, please see Supplemental Experi-
mental Procedures.
FACS Analysis
Cells were dissociated with trypsin, washed, and resuspended in PBS as
single-cell suspension. Cells were then stained with indicated dye/antibodies:
Hoechst 33342 (sigma), anti-CD24-PE (BD PharMingen), anti-CD44-FITC, and
CD44-APC (BD PharMingen). To analyze activated b-catenin, cells were
stained with surface markers (CD24 and CD44), fixed, permeabilized, and
then stained with antiunphosphorylated b-catenin (8E4) (Axxora), anti-EZH2
(Cell Signaling), anti-p-ERK (Cell Signaling), RAF1, g-H2AX, BrdU-FITC,
BrdU-PE (BD Transduction Laboratories). These cells were washed twice
and then stained with secondary antibodies conjugated with APC or PerCP-
Cy5.5 (Jackson ImmunoResearch). The immunoflourescence was evaluated
by BD FACS Canto II (BD Immunocytometry Systems) and analyzed byFCS3 Express Research Lite Edition (Denovo Software). Cell sorting was per-
formed by BD FACS Aria.
Mammary Xenograft Tumor
Mammary fat pads of female NOD/SCID mice were inoculated with indicated
number of isolated CD44+CD24-/low cells or non-CD44+CD24-/low cells for
a total volume of 100 ml per injection site. After 12 weeks, all of the tumors
were calculated and animals were sacrificed. For the in vivo treatment,
AZD6244 or sorafenib prepared as described in the previous studies (Huynh
et al., 2010) was given orally to the mice that had been inoculate with 105
CD44+CD24-/low cells with the indicated doses when the tumors were grown
for 2 weeks (tumor size 50 mm3). All surgical procedures and animal manipu-
lations were performed under regulations of Division of Laboratory Animal
Medicine at The University of Texas M.D. Anderson Cancer Center. Animal
protocols (#06-87-06138) were reviewed and approved by the Institutional
Animal Care and Use Committee at The University of Texas M. D. Anderson
Cancer Center.
IHC Staining and Fluorescence In Situ Hybridization Analysis
Immunohistochemical staining was performed as previously described (Ding
et al., 2005). FISH was performed on paraffin-embedded breast tumor slides
or freshly isolated BTICs following standard protocols. A RAF1 plasmid labeled
with green fluorescence by nick-translation was used as probe. RAF1 signal
(green) to CEP3 (red) signal ratio >2 was considered as amplification. For as-
saying inverted duplication, BAC clones covering RAF1 gene (RP11-275J11,
red) and co-amplified marker centromeric to RAF1 (RP11-767C1, green)
were used as probes.
Antibody Array
The Panorama Ab Microarray-Cell Signaling was purchased from Sigma-
Aldrich. Microarray images were analyzed with the GenePixTM Pro 4.0 image
analysis software. Fluorescence intensity measurements were normalized
with local background, and cytoskeleton antibodies (actins, tubulins) were
used for normalization of total protein quantity between samples.
SNP Array
SNP array analysis was performed using Affymetrix 6.0 arrays and the data
were analyzed and plotted by Partek Genomic Suite (Partek Incorporated).
All vector control samples were examined against HapMap normal data sets
(Affymetrix) and no RAF1 amplification was observed in any of them.
Statistical Analysis
All data were presented as means ± standard deviation of the mean (SD).
Statistical calculations were performed with Microsoft Excel analysis tools.
Differences between individual groups were analyzed by paired t test. P values
of <0.05 considered statistically significant.
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(A) Protein expression change in BTIC enriched-human primary tumor cells expressing RAF1-shRNAs was examined using Immunoblotting, and the percentage
of CD44+CD24-/low cells was determined using flow cytometry.
(B) Bar graph showing the percentage of CD44+CD24-/low population from human primary tumor cells treatedwith different doses of AZD6244. Survivingmammo-
spheres were counted after being treated with different doses of AZD6244 for 48 hr, and shown as representative microscopy images (10 mM AZD6244)
(scale bar: 100 mm).
(C) Bars showing percentage of p-ERK and unphosphorylated b-catenin expression in CD44+CD24-/low cells expressing EZH2 with or without 10 mM AZD6244
using intracellular staining.
(D) NOD/SCID mice (n = 5/group) inoculated with CD44+CD24-/low cells isolated from human primary tumor cells expressing EZH2. Mice bearing tumors for
2 weeks (tumor size 50 mm3) were treated with the indicated doses of AZD6244 daily for 1 week. Tumor sections were subjected to H&E and p-ERK staining
(N: nuclear staining, n = 20/tumor) (scale bar: 20 mm).
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